Case File
efta-efta00777778DOJ Data Set 9OtherFrom: Jeffrey Epstein <jeevacation(r gmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00777778
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <jeevacation(r gmail.com>
To: '
Subject: please respond
Date: Sat, 30 Oct 2010 09:14:20 +0000
This looks extremely high risk and without any real possibility of high reward even based on
this very limited information.
1) Insulin market is very competitive with many very well funded players looking at biosimilar and bio-
same insulin
2) This is very early - recent IND approval from US FDA means they are not in human trials yet or just
started very recently though I suspect if they had actually started human trials they would jhave
mentioned it here.
3) These guys dont seem to have US rights but seem to have rights in low value geographies - you
arent going to make much money selling their product in Iraq, Algeria and Libya etc.
4) Even if they had global rights it is extremely difficult to get AB rated bio-same approval for proteins
and it would be extremely difficult to get comfortable with them achieving that down the road
regardless of how much due diligence you could do now.
5) Insulin competition isnt about manufacturing cost of the active pharmaceutical ingredient but it is
based on the delivery device.
6) No information is given on oral insulin but many have tried for decades and failed and I suspect the
lack of information means they are not in human trials and have not proven any concept. They
actually say here the low cost of their insulin is what opens up the possibility of oral insulin -
that is totally false. The lack of oral insulin products today is based on technical and scientific
hurdles of delivering it intact to the bloodstream through the GI tract - not cost.
***********************************************************
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacationqi)gmail.com and
destroy this communication and all copies thereof,
including all attachments.
EFTA00777778
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
gmail.comRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.